Mark Lynch

20.0k total citations · 4 hit papers
90 papers, 7.7k citations indexed

About

Mark Lynch is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Mark Lynch has authored 90 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 28 papers in Oncology and 12 papers in Surgery. Recurrent topics in Mark Lynch's work include Cancer Immunotherapy and Biomarkers (16 papers), Head and Neck Cancer Studies (10 papers) and Multiple Myeloma Research and Treatments (8 papers). Mark Lynch is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Head and Neck Cancer Studies (10 papers) and Multiple Myeloma Research and Treatments (8 papers). Mark Lynch collaborates with scholars based in United States, United Kingdom and Italy. Mark Lynch's co-authors include Scott M. Wilhelm, Lila Adnane, Jacques Dumas, Philippa Newell, Augusto Villanueva, Josep M. Llovet, Dean Wilkie, Charles Chen, Timothy B. Lowinger and Brian Schwartz and has published in prestigious journals such as Science, New England Journal of Medicine and Nucleic Acids Research.

In The Last Decade

Mark Lynch

90 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

2006 1.4k citations Scott M. Wilhelm, Christopher Carter et al. Nature Reviews Drug Discovery profile →
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5

2006 1.3k citations Scott M. Wilhelm, Mark Lynch et al. Cancer Research profile →
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

2008 1.1k citations Scott M. Wilhelm, Lila Adnane et al. Molecular Cancer Therapeutics profile →
Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

2010 1.0k citations Scott M. Wilhelm, Jacques Dumas et al. profile →

Peers

Countries citing papers authored by Mark Lynch

Since Specialization

Citations

This map shows the geographic impact of Mark Lynch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lynch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lynch more than expected).

Fields of papers citing papers by Mark Lynch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lynch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lynch. The network helps show where Mark Lynch may publish in the future.

Co-authorship network of co-authors of Mark Lynch

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lynch. A scholar is included among the top collaborators of Mark Lynch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lynch. Mark Lynch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Synergy Assessment of Four Antimicrobial Bioactive Compounds for the Combinational Treatment of Bacterial Pathogens 2023 ·Biomedicines ·(unknown), Ian Major, Mark Lynch, Neil J. Rowan	5
2	Development of a low-temperature extrusion process for production of GRAS bioactive-polymer loaded compounds for targeting antimicrobial-resistant (AMR) bacteria 2021 ·The Science of The Total Environment ·(unknown), Elaine Meade, Mary Garvey, Mark Lynch, Ian Major, Neil J. Rowan	15
3	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use 2019 ·Clinical Cancer Research ·Robert L. Ferris, Lisa Licitra, Jérôme Fayette, Caroline Even, George R. Blumenschein, Kevin J. Harrington, J. Guigay, Everett E. Vokes, Nabil F. Saba, Robert I. Haddad, S. Ramkumar, Jeffery S. Russell, Peter Brossart, Makoto Tahara, A. Dimitrios Colevas, Fernando Concha‐Benavente, Mark Lynch, Li Li, Maura L. Gillison	115
4	Integrated Fluidic Circuits for Single-Cell Omics and Multi-omics Applications 2019 ·Advances in experimental medicine and biology ·Mark Lynch, Naveen Ramalingam	6
5	Surface layer proteins from virulent Clostridium difficile ribotypes exhibit signatures of positive selection with consequences for innate immune response 2017 ·BMC Evolutionary Biology ·Mark Lynch, Thomas Walsh, (unknown), Andrew E. Webb, (unknown), Thomas R. Rogers, Henry J. Windle, Dermot Kelleher, Mary J. O’Connell, Christine E. Loscher	17
6	A Role for TLR4 in Clostridium difficile Infection and the Recognition of Surface Layer Proteins 2011 ·PLoS Pathogens ·Anthony W. Ryan, Mark Lynch, Sinéad M. Smith, Sylvie Amu, Hendrik J. Nel, Claire E. McCoy, Jennifer K. Dowling, Eve Draper, Vincent O’Reilly, (unknown), Julie O’Brien, Déirdre Ní Eidhin, Mary J. O’Connell, Brian Keogh, Oliver Morton, Thomas R. Rogers, Padraic G. Fallon, Luke O'neill, Dermot Kelleher, Christine E. Loscher	156
7	Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion 2009 ·Molecular Cancer ·Satish Cheepala, Weihong Yin, (unknown), (unknown), (unknown), Heather E. Kleiner, Mark Lynch, Rasiah Loganantharaj, Marjan Trutschl, Urška Cvek, John L. Clifford	41
8	Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 2008 ·Cancer Research ·Mara Bonelli, Claudia Fumarola, Roberta Alfieri, Rita Gatti, Silvana Belletti, Silvia La Monica, Maricla Galetti, Andrea Cavazzoni, (unknown), Alberto Bottini, (unknown), Mark Lynch, Adrian L. Harris, Stephen B. Fox, Daniele Generali	1
9	Preclinical characterization of BAY 73-4506: A kinase inhibitor with broad spectrum antitumor activity targeting oncogenic and angiogenic kinases 2007 ·Molecular Cancer Therapeutics ·Scott M. Wilhelm, Lila Adnane, Claudia Hirth‐Dietrich, Paul H. Ehrlich, Mark Lynch	5
10	Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006) 2006 ·Cancer Research ·Joan Levy, (unknown), Déborah Braun, Mary DeRome, (unknown), Hong Shi, Daniel C. Weaver, Yong S. Chang, Elizabeth Bortolon, Arris J. Henderson, (unknown), Amy Burd, James J. Elting, Mark Lynch, Sanjeeva Reddy, Scott M. Wilhelm	25
11	Discovery and development of sorafenib: a multikinase inhibitor for treating cancer breakdown → 2006 ·Nature Reviews Drug Discovery ·Scott M. Wilhelm, Christopher Carter, Mark Lynch, Timothy B. Lowinger, Jacques Dumas, Roger A. Smith, Brian Schwartz, Ronit Simantov, Susan L. Kelley	1447
12	Youth Justice: Criminal Trajectories 2003 ·Trends and issues in crime and criminal justice ·Mark Lynch, (unknown), (unknown)	41
13	Gender and official statistics: the juvenile justice system in Queensland, 1998-99 2000 ·Trends and issues in crime and criminal justice ·Emma Ogilvie, Mark Lynch, Sue Anne Bell	2
14	Regulation of Transforming Growth Factor α Expression in a Growth Factor-Independent Cell Line 1998 ·Molecular and Cellular Biology ·Gillian Howell, Lisa E. Humphrey, Barry L. Ziober, Rana Awwad, (unknown), Alan Koterba, Wenhui Li, James K. V. Willson, Kevin Coleman, Joan M. Carboni, Mark Lynch, Michael G. Brattain	16
15	When your patient talks about suicide. 1994 ·PubMed ·Mark Lynch	1
16	Reducing the loss of implants following penile prosthetic surgery* 1994 ·British Journal of Urology ·Mark Lynch, G.M. Scott, (unknown), J. P. PRYOR	29
17	Vasitis Nodosa due to Torture 1993 ·British Journal of Urology ·David Ralph, Mark Lynch, (unknown)	14
18	Hidden dangers in apparently stable neck injuries 1993 ·Injury ·(unknown), (unknown), Mark Lynch	1
19	Cancer cell binding to E-selectin transfected human endothelia 1992 ·Biochemical and Biophysical Research Communications ·June Rae Merwin, Joseph A. Madri, Mark Lynch	10
20	Lipofectin Enhances Cellular Uptake of Antisense DNA While Inhibiting Tumor Cell Growth 1992 ·PubMed ·Lynn C. Yeoman, (unknown), Mark Lynch	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact